BioSpace News Archive

Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the following investor conferences.

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the LD Micro Invitational Conference.

Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, today announced the appointment of Drew Young as Chief Commercial Officer and Head of Patient Experience.

VBI Vaccines Inc. today announced that an abstract has been accepted for oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022.

Veracyte, Inc. announced that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.

The successful completion of Awakn’s behavioral addictions study was announced last week and the data provided from the study was used in the patent filing.

Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced that two new health system partners.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that 100 years of clinical evidence supporting the use of proenzymes as a new therapeutic approach to treat cancer can be considered ‘compelling’.

According to Vision Research Reports, the U.S. office-based labs market size was estimated at around USD 9.7 billion in 2021 and it is projected to hit around USD 18.5 billion by 2030, growing at a CAGR of 7.44% from 2022 to 2030.

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.